Bristol-Myers Squibb Reports Record First Quarter Sales & Earnings

- Sales Increased 5% (8% excluding foreign exchange) to $4.7 Billion from

Continuing Operations

- U.S. Pharmaceutical Sales Up 13%

- Worldwide Pharmaceutical Sales Up 8% (10% excluding foreign exchange)

- Diluted Earnings Per Share from Continuing Operations Increased 13% to

$.63

- Pharmaceutical Research and Development Spending Increased 17% to

$495 Million



Apr 25, 2001, 01:00 ET from Bristol-Myers Squibb

    NEW YORK, April 25 /PRNewswire/ -- Bristol-Myers Squibb Company
 (NYSE:   BMY) today reported sales and earnings for the quarter ended
 March 31, 2001.
     "As reflected by the first quarter results, Bristol-Myers Squibb is off to
 a solid start in fulfilling our commitment to meet or exceed earnings per
 share growth expectations for 2001.  We remain comfortable with current
 consensus estimates of $2.41 for diluted earnings per share for the year,"
 said Charles A. Heimbold, Jr., chairman and chief executive officer.  "Our
 growth strategy remains focused on our core Medicines business where we saw
 very good double-digit pharmaceutical sales growth of 10% worldwide, excluding
 foreign exchange, with especially good growth of 13% in the U.S.  Notable
 drivers of that growth included the GLUCOPHAGE(R) product line, increasing 31%
 with sales of $557 million, PLAVIX(R), up 48% to $298 million, AVAPRO(R), up
 28% to $111 million and PRAVACHOL(R), up 10% with sales of $507 million in the
 quarter."
     "Our ongoing commitment to scientific leadership was underscored with a
 significant increase of 17% in pharmaceutical R&D spending during the quarter.
 We anticipate FDA approval for the new irritable bowel syndrome drug,
 tegaserod, which we have agreed to copromote with its developer, Novartis.
 Also, we expect to be seeking approval for ABILITAT(TM), for schizophrenia,
 and subject to the review of data from the most recent clinical trials -- for
 VANLEV(TM), to treat hypertension.  The divestitures of Zimmer and Clairol are
 progressing according to plan and should be completed on schedule."
 
     FIRST QUARTER RESULTS
     Sales from continuing operations for the quarter grew 5% (8% excluding
 foreign exchange) to $4.7 billion from $4.5 billion in 2000.  The consolidated
 sales growth resulted from a 5% increase due to volume, a 3% increase due to
 changes in selling prices, and a 3% decrease due to foreign exchange rate
 fluctuations.
     For the quarter, earnings before income taxes from continuing operations
 increased 10% to $1,687 million from $1,530 million a year ago.  Net earnings
 from continuing operations increased 10% to $1,243 million compared to
 $1,129 million in 2000. Basic earnings per share increased 12% to $.64 from
 $.57 in the prior year and diluted earnings per share increased 13% to
 $.63 from $.56.  Basic and diluted average shares outstanding for the quarter
 were 1,948 million and 1,978 million, respectively, compared to 1,976 million
 and 2,009 million, respectively, in 2000. During the quarter, the company
 repurchased 11 million shares of common stock at a cost of $668 million.
 
     SALES RESULTS - CONTINUING OPERATIONS
 
     WORLDWIDE PHARMACEUTICAL SALES INCREASED 8% TO $3.7 BILLION
 
     --    U.S. pharmaceutical sales increased 13% and international
           pharmaceutical sales decreased 4% (a 4% increase excluding foreign
           exchange), resulting in a worldwide pharmaceuticals sales increase
           of 8% (10% excluding foreign exchange). Within the U.S., Primary
           Care sales increased 19% to $1,856 million.
 
     --    GLUCOPHAGE(R) is the leading branded oral medication for treatment
           of non-insulin dependent (type 2) diabetes. The entire GLUCOPHAGE
           franchise continued its strong growth rate, with sales increasing
           31% to $557 million.  GLUCOPHAGE sales increased 22% to $519 million
           while GLUCOVANCE(R), launched in August 2000, and GLUCOPHAGE(R) XR,
           launched in October 2000, had sales of $24 million and $14 million,
           respectively. Since their launch, GLUCOVANCE sales have been
           $134 million and GLUCOPHAGE XR sales have been $64 million.
 
     --    Worldwide sales of PRAVACHOL(R), a cholesterol-lowering agent,
           increased 10% to $507 million.
 
     --    Sales of TAXOL(R) (paclitaxel), the company's leading anti-cancer
           agent, decreased 14% to $330 million. Domestic sales decreased 28%
           to $179 million, due to generic competition while international
           sales increased 9% (20% excluding foreign exchange) to $151 million,
           led by strong sales growth in Japan and France.
 
     --    Sales of PLAVIX(R), a platelet aggregation inhibitor for the
           reduction of stroke, heart attack and vascular death in
           atherosclerotic patients with recent stroke, recent heart attack or
           peripheral arterial disease, increased 48% to $298 million.  In
           March 2001, the results of the CURE trial (Clopidogrel in Unstable
           Angina to Prevent Recurrent Ischemic Events) demonstrated that
           PLAVIX dramatically reduces the risk of heart attack, stroke and
           cardiovascular death by 20% in patients with acute coronary
           syndrome. The company anticipates the filing of a supplemental
           application with the FDA for a new indication based upon this study.
           Sales of AVAPRO(R), an angiotensin II receptor blocker for the
           treatment of hypertension, increased 28% to $111 million. AVAPRO and
           PLAVIX are cardiovascular products that were launched from the
           Bristol-Myers Squibb and Sanofi-Synthelabo joint venture.
 
     --    Sales of BUSPAR(R), an anti-anxiety agent, increased 25% to
           $203 million.  Sales of SERZONE(R), a novel anti-depressant,
           increased 10% to $96 million.
 
     --    Sales of the anti-cancer agent PARAPLATIN(R) increased 21% to
           $193 million as the product continues to benefit from its use in
           combination with other chemotherapy agents.
 
     --    Sales of TEQUIN(R), a quinolone antibiotic, were $69 million
           compared with $15 million in the same period of 2000.
 
     --    Sales of VIDEX(R), an anti-retroviral agent, increased 33% to
           $60 million due to increased sales of VIDEX(R) EC enteric-coated
           beadlets launched in 2000.
 
     --    Sales of Oncology Therapeutics Network, a specialty distributor of
           anti-cancer medicines and related products, were $322 million, an
           increase of 32% over the prior year.
 
     --    Nutritional sales decreased 1% to $502 million from $506 million in
           2000 (a 2% increase excluding foreign exchange) as international
           sales increased 9% (15% excluding foreign exchange) and U.S. sales
           decreased 6%. Mead Johnson continues to be the leader in the U.S.
           infant formula market. ENFAMIL(R), the company's largest-selling
           infant formula, recorded sales of $212 million, an increase of 4%
           from the prior year.
 
     --    ConvaTec sales increased 4% (10% excluding foreign exchange) to
           $169 million.  Sales of ostomy products increased 6% (12% excluding
           foreign exchange) to $104 million while sales of modern wound care
           products increased 5% (11% excluding foreign exchange) to
           $60 million.
 
     SALES RESULTS - DISCONTINUED OPERATIONS
 
     CLAIROL ACHIEVED SALES OF $461 MILLION
 
     --    Clairol sales increased 3% (5% excluding foreign exchange) to
           $461 million.  Domestic sales increased 3% while international sales
           increased 3% (8% excluding foreign exchange).  Clairol continues to
           be the number one hair products company in the U.S.
 
     ZIMMER ACHIEVED STRONG SALES GROWTH OF 10% to $286 MILLION
 
     --    Zimmer sales increased 10% (13% excluding foreign exchange) to
           $286 million. Domestic sales increased 16% while international sales
           increased 1% (10% excluding foreign exchange). Sales of knee joint
           replacements increased 12% to $114 million, hip replacement sales
           increased 15% to $92 million, and fracture management product sales
           rose 8% to $40 million.
 
     This press release includes certain forward-looking statements within the
 meaning of the Private Securities Litigation Reform Act of 1995 regarding,
 among other things, statements relating to goals, plans and projections
 regarding the company's financial position, results of operations, market
 position, product development and business strategy.  These statements may be
 identified by the fact that they use words such as "anticipate," "estimate,"
 "expect," "project," "intend," "plan," "believe," and other words and terms of
 similar meaning in connection with any discussion of future operating or
 financial performance.  Such forward-looking statements are based on current
 expectations and involve inherent risks and uncertainties, including factors
 that could delay, divert or change any of them, and could cause actual
 outcomes and results to differ materially from current expectations.  These
 factors include, among other things, market factors, competitive product
 development, governmental regulations and legislation, patent positions and
 litigation.  For further details and a discussion of these and other risks and
 uncertainties, see the company's Securities and Exchange Commission filings,
 including the company's 2000 annual report on Form 10-K.  We undertake no
 obligation to publicly update any forward-looking statement, whether as a
 result of new information, future events or otherwise.
 
     GLUCOPHAGE(R) and GLUCOVANCE(R) are trademarks of Lipha S.A.
     AVAPRO(R) and PLAVIX(R) are trademarks of Sanofi-Synthelabo
 
                          BRISTOL-MYERS SQUIBB COMPANY
                  CONDENSED CONSOLIDATED STATEMENT OF EARNINGS
               FOR THE THREE MONTHS ENDED MARCH 31, 2001 and 2000
          (Unaudited, in millions of dollars except per share amounts)
 
                                                Three Months
                                                Ended March 31,
                                    -------------------------------------
                                                                        %
                                        2001            2000      Increase
 
                                    --------        --------    ----------
     Net Sales                        $4,689          $4,451             5
 
                                   ---------       ---------     ---------
 
     Cost of products sold             1,283           1,141            12
     Marketing, selling,
      administrative and other (a)       834             944          (12)
     Advertising and product promotion   377             390           (3)
     Research and development            508             446            14
 
                                   ---------        --------     ---------
                                       3,002           2,921             3
 
                                   ---------       ---------     ---------
     Earnings from Continuing Operations
     Before Income Taxes               1,687           1,530            10
 
     Provision for income taxes          444             401
 
                                   ---------       ---------     ---------
     Earnings from Continuing
      Operations                      $1,243          $1,129            10
 
     Discontinued Operations, net (a)     93              92
 
                                   ---------       ---------
     Net Earnings                     $1,336          $1,221
 
                                       =====           =====
 
     Earnings Per Common Share:
     Basic
     Earnings from Continuing
      Operations                       $ .64           $ .57            12
                                                                       ===
     Discontinued Operations             .05             .05
 
                                   ---------       ---------
     Net Earnings                      $ .69           $ .62            11
 
                                       =====           =====           ===
     Average Common Shares
     Outstanding (in millions)         1,948           1,976
 
                                       =====           =====
     Diluted
     Earnings from Continuing
      Operations                       $ .63           $ .56            13
                                                                       ===
     Discontinued Operations             .05             .05
 
                                   ---------       ---------
     Net Earnings                      $ .68           $ .61            11
                                       =====           =====           ===
     Average Common Shares
     Outstanding (in millions)         1,978           2,009
 
                                       =====           =====
 
     (a)   In the first quarter 2000, the company recorded a pretax gain of
           $120 million related to the sale of three pharmaceutical
           products -- Estrace Cream, Ovcon 35, and Ovcon 50 in marketing,
           selling, administrative and other in continuing operations.  The
           company also recorded a charge of $120 million, of which
           $102 million is included in marketing, selling, administrative and
           other in continuing operations and $18 million is included in
           discontinued operations.
 
     (b)   For the quarter ended March 31, 2001 and 2000, excluding the
           restructuring charge, the net sales and net earnings from
           discontinued operations are summarized as follows:
 
                                                          Three Months
                                                         Ended March 31,
                                                      ---------------------
 
                                                         2001           2000
                                                      -------        -------
 
     Discontinued Operations:
 
     Net Sales (a)                                       $747           $809
 
                                                         ====           ====
 
 
     Earnings before income taxes (b)                    $150           $166
 
     Provision for income taxes                            57             63
 
                                                      -------        -------
     Net Earnings                                         $93           $103
 
                                                         ====           ====
 
     (a)   In 2000, the company sold its Matrix Essentials Inc. subsidiary and
           its Seabreeze brand in Japan. Sales of these divested
           businesses/products, included above, were $102 million for the first
           three months of 2000. Excluding these sales, discontinued operations
           sales increased 6% (8% excluding foreign exchange)
 
     (b)   In 2001, earnings before income taxes includes $6 million in costs
           related to the spin-off of Zimmer. In 2000, earnings before income
           taxes includes earnings of $13 million from the Matrix subsidiary
           and Seabreeze brand in Japan.
 
 
                          BRISTOL-MYERS SQUIBB COMPANY
                      SELECTED PRODUCTS - WORLDWIDE TOTALS
                   FOR THE THREE MONTHS ENDED MARCH 31, 2001
                      (Unaudited, in millions of dollars)
 
                                                   -------First Quarter------
                                                         2001        Percent
                                                        Sales       Increase
                                                  -----------     ----------
 
     GLUCOPHAGE                                          $557*           31%
 
     PRAVACHOL                                            507            10%
 
     PLAVIX                                               298            48%
 
     BUSPAR                                               203            25%
 
     PARAPLATIN                                           193            21%
 
     AVAPRO                                               111**          28%
 
     OSTOMY                                               104             6%
 
     SERZONE                                               96            10%
 
     TEQUIN                                                69           ****
 
     WOUND CARE                                            60             5%
 
     VIDEX                                                 60***         33%
 
 
        *  Includes GLUCOPHAGE(R) IR, GLUCOPHAGE(R) XR and GLUCOVANCE(TM)
       **  Includes Avalide
      ***  Includes VIDEX(R) and VIDEX(R) EC
     ****  in excess of 200%
 
                     MAKE YOUR OPINION COUNT -- Click Here
                http://tbutton.prnewswire.com/prn/11690X61184374
 
 

SOURCE Bristol-Myers Squibb
    NEW YORK, April 25 /PRNewswire/ -- Bristol-Myers Squibb Company
 (NYSE:   BMY) today reported sales and earnings for the quarter ended
 March 31, 2001.
     "As reflected by the first quarter results, Bristol-Myers Squibb is off to
 a solid start in fulfilling our commitment to meet or exceed earnings per
 share growth expectations for 2001.  We remain comfortable with current
 consensus estimates of $2.41 for diluted earnings per share for the year,"
 said Charles A. Heimbold, Jr., chairman and chief executive officer.  "Our
 growth strategy remains focused on our core Medicines business where we saw
 very good double-digit pharmaceutical sales growth of 10% worldwide, excluding
 foreign exchange, with especially good growth of 13% in the U.S.  Notable
 drivers of that growth included the GLUCOPHAGE(R) product line, increasing 31%
 with sales of $557 million, PLAVIX(R), up 48% to $298 million, AVAPRO(R), up
 28% to $111 million and PRAVACHOL(R), up 10% with sales of $507 million in the
 quarter."
     "Our ongoing commitment to scientific leadership was underscored with a
 significant increase of 17% in pharmaceutical R&D spending during the quarter.
 We anticipate FDA approval for the new irritable bowel syndrome drug,
 tegaserod, which we have agreed to copromote with its developer, Novartis.
 Also, we expect to be seeking approval for ABILITAT(TM), for schizophrenia,
 and subject to the review of data from the most recent clinical trials -- for
 VANLEV(TM), to treat hypertension.  The divestitures of Zimmer and Clairol are
 progressing according to plan and should be completed on schedule."
 
     FIRST QUARTER RESULTS
     Sales from continuing operations for the quarter grew 5% (8% excluding
 foreign exchange) to $4.7 billion from $4.5 billion in 2000.  The consolidated
 sales growth resulted from a 5% increase due to volume, a 3% increase due to
 changes in selling prices, and a 3% decrease due to foreign exchange rate
 fluctuations.
     For the quarter, earnings before income taxes from continuing operations
 increased 10% to $1,687 million from $1,530 million a year ago.  Net earnings
 from continuing operations increased 10% to $1,243 million compared to
 $1,129 million in 2000. Basic earnings per share increased 12% to $.64 from
 $.57 in the prior year and diluted earnings per share increased 13% to
 $.63 from $.56.  Basic and diluted average shares outstanding for the quarter
 were 1,948 million and 1,978 million, respectively, compared to 1,976 million
 and 2,009 million, respectively, in 2000. During the quarter, the company
 repurchased 11 million shares of common stock at a cost of $668 million.
 
     SALES RESULTS - CONTINUING OPERATIONS
 
     WORLDWIDE PHARMACEUTICAL SALES INCREASED 8% TO $3.7 BILLION
 
     --    U.S. pharmaceutical sales increased 13% and international
           pharmaceutical sales decreased 4% (a 4% increase excluding foreign
           exchange), resulting in a worldwide pharmaceuticals sales increase
           of 8% (10% excluding foreign exchange). Within the U.S., Primary
           Care sales increased 19% to $1,856 million.
 
     --    GLUCOPHAGE(R) is the leading branded oral medication for treatment
           of non-insulin dependent (type 2) diabetes. The entire GLUCOPHAGE
           franchise continued its strong growth rate, with sales increasing
           31% to $557 million.  GLUCOPHAGE sales increased 22% to $519 million
           while GLUCOVANCE(R), launched in August 2000, and GLUCOPHAGE(R) XR,
           launched in October 2000, had sales of $24 million and $14 million,
           respectively. Since their launch, GLUCOVANCE sales have been
           $134 million and GLUCOPHAGE XR sales have been $64 million.
 
     --    Worldwide sales of PRAVACHOL(R), a cholesterol-lowering agent,
           increased 10% to $507 million.
 
     --    Sales of TAXOL(R) (paclitaxel), the company's leading anti-cancer
           agent, decreased 14% to $330 million. Domestic sales decreased 28%
           to $179 million, due to generic competition while international
           sales increased 9% (20% excluding foreign exchange) to $151 million,
           led by strong sales growth in Japan and France.
 
     --    Sales of PLAVIX(R), a platelet aggregation inhibitor for the
           reduction of stroke, heart attack and vascular death in
           atherosclerotic patients with recent stroke, recent heart attack or
           peripheral arterial disease, increased 48% to $298 million.  In
           March 2001, the results of the CURE trial (Clopidogrel in Unstable
           Angina to Prevent Recurrent Ischemic Events) demonstrated that
           PLAVIX dramatically reduces the risk of heart attack, stroke and
           cardiovascular death by 20% in patients with acute coronary
           syndrome. The company anticipates the filing of a supplemental
           application with the FDA for a new indication based upon this study.
           Sales of AVAPRO(R), an angiotensin II receptor blocker for the
           treatment of hypertension, increased 28% to $111 million. AVAPRO and
           PLAVIX are cardiovascular products that were launched from the
           Bristol-Myers Squibb and Sanofi-Synthelabo joint venture.
 
     --    Sales of BUSPAR(R), an anti-anxiety agent, increased 25% to
           $203 million.  Sales of SERZONE(R), a novel anti-depressant,
           increased 10% to $96 million.
 
     --    Sales of the anti-cancer agent PARAPLATIN(R) increased 21% to
           $193 million as the product continues to benefit from its use in
           combination with other chemotherapy agents.
 
     --    Sales of TEQUIN(R), a quinolone antibiotic, were $69 million
           compared with $15 million in the same period of 2000.
 
     --    Sales of VIDEX(R), an anti-retroviral agent, increased 33% to
           $60 million due to increased sales of VIDEX(R) EC enteric-coated
           beadlets launched in 2000.
 
     --    Sales of Oncology Therapeutics Network, a specialty distributor of
           anti-cancer medicines and related products, were $322 million, an
           increase of 32% over the prior year.
 
     --    Nutritional sales decreased 1% to $502 million from $506 million in
           2000 (a 2% increase excluding foreign exchange) as international
           sales increased 9% (15% excluding foreign exchange) and U.S. sales
           decreased 6%. Mead Johnson continues to be the leader in the U.S.
           infant formula market. ENFAMIL(R), the company's largest-selling
           infant formula, recorded sales of $212 million, an increase of 4%
           from the prior year.
 
     --    ConvaTec sales increased 4% (10% excluding foreign exchange) to
           $169 million.  Sales of ostomy products increased 6% (12% excluding
           foreign exchange) to $104 million while sales of modern wound care
           products increased 5% (11% excluding foreign exchange) to
           $60 million.
 
     SALES RESULTS - DISCONTINUED OPERATIONS
 
     CLAIROL ACHIEVED SALES OF $461 MILLION
 
     --    Clairol sales increased 3% (5% excluding foreign exchange) to
           $461 million.  Domestic sales increased 3% while international sales
           increased 3% (8% excluding foreign exchange).  Clairol continues to
           be the number one hair products company in the U.S.
 
     ZIMMER ACHIEVED STRONG SALES GROWTH OF 10% to $286 MILLION
 
     --    Zimmer sales increased 10% (13% excluding foreign exchange) to
           $286 million. Domestic sales increased 16% while international sales
           increased 1% (10% excluding foreign exchange). Sales of knee joint
           replacements increased 12% to $114 million, hip replacement sales
           increased 15% to $92 million, and fracture management product sales
           rose 8% to $40 million.
 
     This press release includes certain forward-looking statements within the
 meaning of the Private Securities Litigation Reform Act of 1995 regarding,
 among other things, statements relating to goals, plans and projections
 regarding the company's financial position, results of operations, market
 position, product development and business strategy.  These statements may be
 identified by the fact that they use words such as "anticipate," "estimate,"
 "expect," "project," "intend," "plan," "believe," and other words and terms of
 similar meaning in connection with any discussion of future operating or
 financial performance.  Such forward-looking statements are based on current
 expectations and involve inherent risks and uncertainties, including factors
 that could delay, divert or change any of them, and could cause actual
 outcomes and results to differ materially from current expectations.  These
 factors include, among other things, market factors, competitive product
 development, governmental regulations and legislation, patent positions and
 litigation.  For further details and a discussion of these and other risks and
 uncertainties, see the company's Securities and Exchange Commission filings,
 including the company's 2000 annual report on Form 10-K.  We undertake no
 obligation to publicly update any forward-looking statement, whether as a
 result of new information, future events or otherwise.
 
     GLUCOPHAGE(R) and GLUCOVANCE(R) are trademarks of Lipha S.A.
     AVAPRO(R) and PLAVIX(R) are trademarks of Sanofi-Synthelabo
 
                          BRISTOL-MYERS SQUIBB COMPANY
                  CONDENSED CONSOLIDATED STATEMENT OF EARNINGS
               FOR THE THREE MONTHS ENDED MARCH 31, 2001 and 2000
          (Unaudited, in millions of dollars except per share amounts)
 
                                                Three Months
                                                Ended March 31,
                                    -------------------------------------
                                                                        %
                                        2001            2000      Increase
 
                                    --------        --------    ----------
     Net Sales                        $4,689          $4,451             5
 
                                   ---------       ---------     ---------
 
     Cost of products sold             1,283           1,141            12
     Marketing, selling,
      administrative and other (a)       834             944          (12)
     Advertising and product promotion   377             390           (3)
     Research and development            508             446            14
 
                                   ---------        --------     ---------
                                       3,002           2,921             3
 
                                   ---------       ---------     ---------
     Earnings from Continuing Operations
     Before Income Taxes               1,687           1,530            10
 
     Provision for income taxes          444             401
 
                                   ---------       ---------     ---------
     Earnings from Continuing
      Operations                      $1,243          $1,129            10
 
     Discontinued Operations, net (a)     93              92
 
                                   ---------       ---------
     Net Earnings                     $1,336          $1,221
 
                                       =====           =====
 
     Earnings Per Common Share:
     Basic
     Earnings from Continuing
      Operations                       $ .64           $ .57            12
                                                                       ===
     Discontinued Operations             .05             .05
 
                                   ---------       ---------
     Net Earnings                      $ .69           $ .62            11
 
                                       =====           =====           ===
     Average Common Shares
     Outstanding (in millions)         1,948           1,976
 
                                       =====           =====
     Diluted
     Earnings from Continuing
      Operations                       $ .63           $ .56            13
                                                                       ===
     Discontinued Operations             .05             .05
 
                                   ---------       ---------
     Net Earnings                      $ .68           $ .61            11
                                       =====           =====           ===
     Average Common Shares
     Outstanding (in millions)         1,978           2,009
 
                                       =====           =====
 
     (a)   In the first quarter 2000, the company recorded a pretax gain of
           $120 million related to the sale of three pharmaceutical
           products -- Estrace Cream, Ovcon 35, and Ovcon 50 in marketing,
           selling, administrative and other in continuing operations.  The
           company also recorded a charge of $120 million, of which
           $102 million is included in marketing, selling, administrative and
           other in continuing operations and $18 million is included in
           discontinued operations.
 
     (b)   For the quarter ended March 31, 2001 and 2000, excluding the
           restructuring charge, the net sales and net earnings from
           discontinued operations are summarized as follows:
 
                                                          Three Months
                                                         Ended March 31,
                                                      ---------------------
 
                                                         2001           2000
                                                      -------        -------
 
     Discontinued Operations:
 
     Net Sales (a)                                       $747           $809
 
                                                         ====           ====
 
 
     Earnings before income taxes (b)                    $150           $166
 
     Provision for income taxes                            57             63
 
                                                      -------        -------
     Net Earnings                                         $93           $103
 
                                                         ====           ====
 
     (a)   In 2000, the company sold its Matrix Essentials Inc. subsidiary and
           its Seabreeze brand in Japan. Sales of these divested
           businesses/products, included above, were $102 million for the first
           three months of 2000. Excluding these sales, discontinued operations
           sales increased 6% (8% excluding foreign exchange)
 
     (b)   In 2001, earnings before income taxes includes $6 million in costs
           related to the spin-off of Zimmer. In 2000, earnings before income
           taxes includes earnings of $13 million from the Matrix subsidiary
           and Seabreeze brand in Japan.
 
 
                          BRISTOL-MYERS SQUIBB COMPANY
                      SELECTED PRODUCTS - WORLDWIDE TOTALS
                   FOR THE THREE MONTHS ENDED MARCH 31, 2001
                      (Unaudited, in millions of dollars)
 
                                                   -------First Quarter------
                                                         2001        Percent
                                                        Sales       Increase
                                                  -----------     ----------
 
     GLUCOPHAGE                                          $557*           31%
 
     PRAVACHOL                                            507            10%
 
     PLAVIX                                               298            48%
 
     BUSPAR                                               203            25%
 
     PARAPLATIN                                           193            21%
 
     AVAPRO                                               111**          28%
 
     OSTOMY                                               104             6%
 
     SERZONE                                               96            10%
 
     TEQUIN                                                69           ****
 
     WOUND CARE                                            60             5%
 
     VIDEX                                                 60***         33%
 
 
        *  Includes GLUCOPHAGE(R) IR, GLUCOPHAGE(R) XR and GLUCOVANCE(TM)
       **  Includes Avalide
      ***  Includes VIDEX(R) and VIDEX(R) EC
     ****  in excess of 200%
 
                     MAKE YOUR OPINION COUNT -- Click Here
                http://tbutton.prnewswire.com/prn/11690X61184374
 
 SOURCE  Bristol-Myers Squibb

RELATED LINKS

http://www.bms.com